Adverse effects of intravenous immunoglobulin therapy

Drug Safety

Volumn 21, Issue 3, 1999, Pages 171-185

  Nydegger, Urs E ^a,b   Sturzenegger, Mathias ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b Regional Blood Bank Bern   (Switzerland)

^c Neurologische Universitatsklinik Bern   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN; STABILIZING AGENT;

ARTHRITIS; ASEPTIC MENINGITIS; BRAIN INFARCTION; CHILL; DRUG CONTAMINATION; DRUG TOLERABILITY; DYSPNEA; FEVER; FLUSHING; HEART INFARCTION; HEMOLYSIS; HUMAN; HYPERVISCOSITY SYNDROME; HYPOTENSION; IMMUNOGLOBULIN AGGREGATE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LEUKOPENIA; LUNG TOXICITY; NAUSEA; NEPHROTOXICITY; PAIN; PRION DISEASE; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SKIN TOXICITY; VOMITING;

ANIMALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INJECTIONS, INTRAVENOUS; RISK ASSESSMENT;

EID: 0032886187     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921030-00003     Document Type: Review

References (74)

1. Report of a WHO consultation on medicinal and other products in relation to human and animal transmissible spongiform encephalopathies. Geneva, 24-26 Mar 1997. WHO/BLG 97.2
2. Council of Europe Publishing. 5th ed. 1999. Guide to the preparation, use and quality assurance of blood components. Select Committee of Experts on Quality Assurance in Blood Transfusion Services, Strasbourg (France)
3. The European Agency for the Evaluation of Medicinal Products (EMEA). Note to the CPMP. Risk of transmission of CJD via medicinal products derived from human blood and plasma. Biotechnology Working Party Meeting; 1997 Mar 11-12
4. Barandun S, Isliker H. Development of immunoglobulin preparations for intravenous use. Vox Sang 1986; 51: 157-60
5. Lambert JS, Mofenson LM, Fletcher CV, et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. J Infect Dis 1997; 175: 283-91
6. Ambre JJ, Bennett DR, Crauston JW, et al. Adverse Drug Events. In: AMA drug evaluations annual 1995. American Medical Association, 1995: 39-50
7. Schaffer CH, Blanhé-Ganter E. Qualität polyvalenter immunglobuline. Ergebnisse einer umfrage. Krankenhauspharmazie 1998; 19: 280-6
8. Bertorini TE, Nance AM, Horner LA, et al. Complications of intravenous gammaglubulin in neuromuscular and other diseases. Muscle Nerve 1996; 19: 388-91
9. Weisman LE. The safety of intravenous immunoglobulin preparations. Isr J Med Sci 1994; 30: 459-63
10. Brannaghan III TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin in neurologic disease. Neurology 1996; 47: 674-7
11. Schiavotto C, Ruggeri M, Todeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: Incidence in 83 patients treated for idiopathic thrombocylopenic purpura (ITP) and review of the literature. Haematologica 1993; 78 Suppl. 2: 34-40
12. van der Meché FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9
13. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med 1986; 314: 560-4
14. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-62
15. Ember JA, Jagels MA, Hugli TE. Characterization of complement anaphylatoxins and their biological responses. In: Volanakis JE, Frank MM, editors. The human complement system in health and disease (Volanakis). New York: Marcel Dekker, 1998: 83-118
16. Nydegger UE. Immune complexes. In: Delves PJ, Roitt IM, editors. Encyclopedia in immunology. 2nd ed. London: Academic Press. 1998: 1220-5
17. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain Barré syndrome. Lancet 1997; 349: 225-30
18. Bagdasarian A, Tonetta S, Harel W, et al. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang 1998; 74: 74-82
19. Anderson J, Noorby-Teglund A, Koth DE, et al. Modulation of the cytokine network by intravenous immunoglobulin. In: Kazatchkine MD, Morell A, editors. Intravenous immunoglobulins research and therapy. New York, London; Parthenon Publishing Group 1996: 61-72
20. Wurster U, Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 1994; 57: 21-5
21. Blasczyk KR, Westhoff U, Grosse-Wilde H, et al. CD8 and HLA molecules in commercial immunoglubulin preparations. Lancet 1993; 341: 789-90
22. Greenbaum BH. Differences in immunoglobulin preparations for intravenous use: a comparison of six products. Am J Pediatr Hematol Oncol 1990; 12: 490-6
23. Björkander J, Hammarström L, Smith CIE, et al. Immunglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 1987; 7: 8-15
24. NIH Consensus Conference. Intravenous immunoglobulin: prevention and treatment of disease. JAMA 1990; 264: 3189-93
25. Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet 1987; 1: 1436
26. Casteels-Van Daele M, Wijndaele L, Huninck K. Intravenous immune globulin and acute aseptic meningitis. N Engl J Med 1990; 323: 614-5
27. Ayliffe W, Haeney M, Roberts SC, et al. Uveilis after anti-neutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy. Lancet 1992; 339: 558-9
28. Nydegger UE. Safety and side effects of i.v. immunoglobulin therapy. Clin Exp Rheumatol 1996; 14: S53-7
29. Schifferli J, Leski M, Favre H, et al. High-dose intravenous IgG treatment and renal function. Lancet 1991; 337: 457-8
30. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 137-9
31. Cantu TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kid Dis 1995; 25: 228-34
32. Windurm P, Bharucha C, Desai ZR. Intravenous immunoglobulin therapy and renal dysfunction. Br J Haematol 1998; 101; 592-6
33. Somer T. Rheology of paraproteinemias and the plasma hyperviscosity syndrome. Baillieres Clin Haematol 1987; 1: 695-723
34. Martin CM, Mallow AG, Chew E, et al. Hyperviscosity syndrome in a patient with acquired immunodeficiency syndrome. Arch Intern Med 1989; 149: 1435-6
35. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 1: 662-4
36. Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997; 124: 614-8
37. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk or precipitating thromboembolic events. Neurology 1994; 44: 223-6
38. Fisman DN, Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 1197; 13: 775-7
39. Steg RE, Lelkowitz, DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994; 44: 1180-1
40. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1192; 42: 257-8
41. Woodruff RK, Gigg AP, Firkin FC, et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986; 11: 217-8
42. Rosenbaum JT. Myocoardial infarction as a complication of immunoglobulin therapy. Arthritis Rheum 1997; 40: 1732-3
43. Suassuna JH, da Costa MA, Faria RA, et al. Noncardiogenic pulmonary edema triggered by intravenous immunoglobulin in cancer-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome [letter]. Nephron 1997; 77: 368-70
44. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-81
45. Yockey SM, Ahmed I. Intravenous immunoglobulin-induced lichenoid dermatitis: a unique adverse reaction. Mayo Clin Proc 1997; 72: 1151-2
46. Whittam LR, Hay RJ, Hughes RA. Eczematous reactions to human immune globulin [letter]. Br J Dermatol 1997; 137: 481-2
47. Stangel M, Hartung HP, Marx P, et al. Side effects of high-duse intravenous immunoglobulins. Clin Neuropharmacol 1997; 20: 385-93
48. Gabor EP. Meningitis and skin reaction after intravenous immune globulin therapy [letter]. Ann Intern Med 1997; 127: 1130
49. Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thromobocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997; 130: 281-283
50. Scribner CL, Kapit RM, Phillips ET, et al. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994; 121: 305-6
51. Hill H, Jolles D. Management of aseptic meningitis secondary to intravenous immunoglobulin [letter]. BMJ 1998; 316: 936
52. Wills AJ, Unsworth DJ. A practical approach to the use of intravenous immunoglobulin in neurological disease. Eur Neurol 1998; 39: 3-8
53. Lisak RP. Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996; 135: 85-8
54. Buchs JP, Nydegger UE. Quantitation of anti-A and anti-B IgG antibodies in therapeutic i.v. immunoglobulin by indirect ELISA. Transfusion Sci 1990; 11: 113-21
55. Brox AG, Cournoyer D, Sternbach M, et al. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987; 82: 633-5
56. Kluge A, Dopfer R, Pfeiffer-Wolf I, et al. Immunoglobulin high-dose therapy: RBC-alloantibodies in commercial preparations and haemolytic anaemia: a case report. Infusionsther Transfusionsmed 1994; 32: 474-5
57. Wilson JR, Bhoopalam H, Fisher M. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve 1997; 20: 1142-5
58. von Allmen E, Richen R, Nydegger UE. Development of Clq ABO-ELISA to measure Clq binding by human anti-A alloantibodies. J Immunol Methods 1994; 171; 85-92
59. Buchs JP, Nydegger UE. Quantitation of anti-A and anti-B IgG antibodies in therapeutic i.v. immunoglobulins by indirect ELISA. Transfus Sci 1990; 11: 113-21
60. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992; 326: 270-1
61. Mitra G, Wong MF, Mozen MM, et al. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion 1986; 26: 394-7
62. Kempff C, Jentsch P, Poirier B, et al. Virus inactivation during production of intravenous immunuglobulins. Transfusion 1991; 31: 423-7
63. Tankersley DL, Mason BL, Guo ZP, et al. Viral safety of intravenous immunoglobulins. In: Kazatchkine MD, Morell A, editors. Intravenous immunoglobulins research and therapy. New York, London; Parthenon Publishing Group, 1996: 3-9
64. Yu MW, Mason BL, Guo ZP, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995; 345: 1173-4
65. Rossi G, Tucci A, Cariani E, et al. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 1997; 90: 1309-14
66. Erdman DD, Anderson BC, Rorok TJ, et al. Possible transmission of parvovirus B19 from intravenous immune globulin. J Med Virol 1997; 53: 233-6
67. Nydegger UE, Hauser SP. Use of intravenous immunoglobulins in haematological disorders. Clin Immunother 1996; 465-85
68. Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996; 104 Suppl. 1: 35-42
69. Schiff RI. Transmission of viral infections through intravenous immune globulin [editorial]. N Engl J Med 1994; 331: 1649-50
70. Saegusa A. UK plays safe on risks from blood products. Nature 1998; 392: 3
71. Klein MA, Frigg R, Flechsig E, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390: 687-90
72. Maring J-A, MacAuley C, Theisen PW, et al. An-/Abreicherung von TSE. Infecktiosität während der Plasmafraktionierung [abstract 37/2m]. Infusionsther Transfusionsmed 1998; 25: 85
73. Dodd RY, Sullivan MT. Creutzfeld-Jakob disease and transfusion safety: tilling at icebergs? Transfusion 1998; 38: 221-3
74. Rowley AG, Shulman ST. Kawasaki syndrome. Clin Microbiol Rev 1998: 11: 405-14